PracticeUpdate: Dermatology - Vol 1 - No.1 - 2017

CONFERENCE COVERAGE 8

2017 American Academy of Dermatology Annual Meeting 3–7 MARCH 2017 • ORLANDO, FLORIDA, USA

The 2017 AAD Annual Meeting sawmore than 1100 speakers present new research and clinical information on the diagnosis and treatment of skin, hair and nail conditions. The PracticeUpdate editorial team and contributors Dr Anna Wile, Dr Sarah Chamlin and Dr Jeffrey Scott, present highlights from the meeting.

2017 AADANNUALMEETING Dr AnnaWile’s take-aways

S068 – Therapeutic and diagnostic pearls What’s new in infectious disease – T Rosen • We could be facing a Zika outbreak this summer in the US. Although there are no FDA-approved treat- ments for Zika, a recent screen of FDA-approved drugs found several that could inhibit Zika infection. These drugs included mycolic acid (pregnancy category D), ivermectin (pregnancy category C), sertraline (pregnancy category C), and daptomycin (pregnancy category B). 1 Areas predicted to be affected are the Gulf Coast and lower Atlantic sea- board. Commercial tests for Zika are now available. The FDA is debating releasing genetically modified male Aedes mosquitoes into the Florida Keys, which would yield nonviable larvae. This has been a suc- cessful tactic in the Cayman Islands and Brazil. • New vaccines to be on the lookout for are the dengue fever vaccine, which is nearly 100% effec- tive, and the nonavalent HPV vaccine. • Syphilis is on the rise and there is a national Bicillin shortage. Minocycline 100 mg twice daily for 28 days is 87.3% effective and a good alternative. • Omadacycline is the first antibiotic in the aminomethyl- cycline class. It has a broad spectrum that includes CRE, VRE, MRSA, VRSA, and clindamycin- and erythro- mycin-resistant strep. It will be available as a single-day oral or IV dosing. It will be highly resistance resistant. 2

Dr Wile, a regular contributor to PracticeUpdate Dermatology , offers her key “take-aways” from the 2017 AAD Annual Meeting.

S045 – Teledermatology working for you: customizing use in the changing healthcare environment. Teledermatology and the future of medicine – C Kovarik • Teledermatology will very likely be a component of the future dermatology landscape, and we should actively participate in its development to ensure a high-quality execution. Preferred modalities include live-interactive and store and forward. • Teledermatology will be a means to deliver care in areas of poor dermatology access and in under- served subspecialties (eg, inpatient dermatology) to improve outcomes. However, we must be vigi- lant to detect poor-quality teledermatology, which could compound our access problems. Unsavoury teledermatology providers could compromise potential opportunities. • We as dermatologists must advocate for payments to us as providers to care for our patients instead of corporate telemedicine dominating the market.

PRACTICEUPDATE DERMATOLOGY